TransMedics Group (NASDAQ:TMDX) Stock Price Down 9.5% - Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) fell 9.5% on Monday . The company traded as low as $62.24 and last traded at $62.26. 622,869 shares were traded during trading, a decline of 83% from the average session volume of 3,603,287 shares. The stock had previously closed at $68.81.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMDX. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a research note on Wednesday, November 20th. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. Baird R W upgraded shares of TransMedics Group to a "strong-buy" rating in a report on Tuesday, September 24th. Oppenheimer restated an "outperform" rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Trading Down 6.9 %

The firm has a 50-day moving average of $73.98 and a 200 day moving average of $120.79. The company has a market cap of $2.15 billion, a P/E ratio of 68.14 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business's quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. On average, analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,459 shares of company stock worth $1,802,244. Corporate insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Driehaus Capital Management LLC boosted its stake in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock worth $223,832,000 after buying an additional 202,867 shares during the last quarter. Principal Financial Group Inc. boosted its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC bought a new position in TransMedics Group in the 2nd quarter valued at $18,854,000. Canada Pension Plan Investment Board purchased a new stake in shares of TransMedics Group during the 2nd quarter valued at $16,086,000. Finally, Public Sector Pension Investment Board bought a new stake in shares of TransMedics Group during the 3rd quarter worth $11,079,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.